文献速递鼻科

下鼻甲减容术与免疫治疗在变应性鼻炎中的成本-效果分析

Cost-effectiveness Analysis of Inferior Turbinate Reduction and Immunotherapy in Allergic Rhinitis.
PubMed 文献 · Laryngoscope · 2023-08-29

该成本-效果分析在5年时间范围内比较了四种治疗方案:继续单纯药物治疗、过敏检测与皮下变应原免疫治疗(SCIT)、SCIT无效后行下鼻甲减容术(ITR)、ITR无效后行过敏检测与SCIT。结果显示,对初始药物治疗无效的变应性鼻炎伴鼻塞患者,优先行ITR(微清创器辅助黏膜下切除或射频消融)再行SCIT最具成本-效果,概率敏感性分析中95.4%的场景支持该策略。

要点

  • 对药物治疗无效的变应性鼻炎伴鼻塞患者,优先ITR再行SCIT最具成本-效果。
  • 概率敏感性分析显示优先ITR再SCIT在95.4%的场景中具成本-效果。
  • 即使同期行鼻中隔成形术,ITR仍具成本-效果。

核心结论

  • 对药物治疗后仍持续存在鼻塞的变应性鼻炎伴特应性下鼻甲肥大患者,ITR具成本-效果,应在免疫治疗前考虑。

研究设计与样本

  • 成本-效果分析,比较四种治疗组合在5年时间范围内的成本-效果,对象为初始药物治疗无效的变应性鼻炎伴特应性鼻塞患者。

主要发现

  • 优先行ITR(微清创器辅助黏膜下切除或射频消融)再行SCIT是最具成本-效果的策略。
  • 概率敏感性分析显示,优先ITR再SCIT在95.4%的场景中是最具成本-效果的选项。
  • 即使同期行鼻中隔成形术,ITR仍具成本-效果。

关键数值与推荐

  • 结果以增量成本-效果比(ICER)报告。

临床怎么用

  • 对药物治疗后仍持续鼻塞的变应性鼻炎伴特应性下鼻甲肥大患者,作者认为ITR具成本-效果,应在免疫治疗前考虑。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Allergic rhinitis (AR) is a common condition that is frequently associated with atopic inferior turbinate hypertrophy (ITH) resulting in nasal obstruction. Current guidelines support the use of subcutaneous allergen immunotherapy (SCIT) when patients fail pharmacologic management. However, there is a lack of consensus regarding the role of inferior turbinate reduction (ITR), a treatment that we hypothesize is cost-effective compared with other available treatments. METHODS: We conducted a cost-effectiveness analysis comparing the following treatment combinations over a 5-year time horizon for AR patients presenting with atopic nasal obstruction who fail initial pharmacotherapy: (1) continued pharmacotherapy alone, (2) allergy testing and SCIT, (3) allergy testing and SCIT and then ITR for SCIT nonresponders, and (4) ITR and then allergy testing and SCIT for ITR nonresponders. Results were reported as incremental cost-effectiveness ratios (ICERs). RESULTS: For patients who fail initial pharmacotherapy, prioritizing ITR, either by microdebrider-assisting submucous resection or radiofrequency ablation, before SCIT was the most cost-effective strategy. Probabilistic sensitivity analysis demonstrated that prioritizing ITR before SCIT was the most cost-effective option in 95.4% of scenarios. ITR remained cost-effective even with the addition of concurrent septoplasty. CONCLUSION: For many AR patients who present with nasal obstruction secondary to atopic inferior turbinate hypertrophy that is persistent despite pharmacotherapy, ITR is a cost-effective treatment that should be considered prior to immunotherapy. LEVEL OF EVIDENCE: NA - Laryngoscope, 2023 Laryngoscope, 134:1572-1580, 2024.

来源:Laryngoscope,查看原文。版权归原作者所有。

引用

  1. Yong M, Aravinthan K, Kirubalingam K, et al. Cost-effectiveness Analysis of Inferior Turbinate Reduction and Immunotherapy in Allergic Rhinitis. Laryngoscope. 2023. PMID: 37642388. doi:10.1002/lary.31003

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。